US Residents
This site is intended for non-US residents only.

Enhance your treatment decisions with intrinsic subtypes

Put your patients’ prognostic information into action

  • Prosigna was developed based on the PAM50 gene signature, which measures the expression of 50 genes to classify tumors into 1 of 4 intrinsic subtypes1
  • Intrinsic subtypes provide valuable prognostic information to guide clinical decisions1,2
  • According to the St. Gallen guidelines, systemic therapy recommendations should follow intrinsic subtype classification2
PAM50 shows luminal A and luminal B subtypes have significantly different rates of DRFS

Intrinsic subtypes: the underlying biology of breast cancer

PAM50 is the accepted standard for subtyping breast cancer3

The Cancer Genome Atlas (TCGA) research network analyzed the gene expression signatures of 525 breast cancer tumors and clustered them into 4 intrinsic subtypes using 3 methods:

  • PAM50 gene signature
  • Unsupervised hierarchical clustering
  • Semi-supervised hierarchical clustering

PAM50 showed high concordance with both the unsupervised (P<0.001) and the semi-supervised (P<0.001) cluster analyses, supporting PAM50's role as a powerful tool for categorizing breast cancer by intrinsic subtype.

The research concluded that diverse genetic and epigenetic alterations converge phenotypically into the following 4 main breast cancer intrinsic subtypes defined by PAM50: luminal A, luminal B, HER2-enriched, and basal-like.

Breast cancer subtypes have distinct gene expression profiles
References: 1. Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013. 2. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-1747. 3. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.